Investing Profile

Mark Chin

InvestorVC
Analyst at JMI Equity
Photo of Mark Chin, Jmi Equity

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Hotmail Network
4899 CONNECTIONS
Hotmail Network
4899 CONNECTIONS
Hotmail Network
4899 CONNECTIONS
The Wharton School Network
430 CONNECTIONS
University of Pennsylvania Network
330 CONNECTIONS
cb
$100K - $5.0M
$1.5M
14
CompanyStageDateRound SizeTotal Raised
Ethyreal Bio
Series BJan 2026$60M
$100M
Co-investors: Michael Gladstone (Atlas Venture), Jernej Godec (Atlas Venture)
Ottimo Pharma
Series ADec 2024$140M
$140M
Co-investors: Peter Thompson (OrbiMed)
Vicebio
Series BSep 2024$100M
$100M
Evommune
Series BApr 2023$50M
$260M
Co-investors: Ash Khanna (Pivotal bioVenture Partners), Rob Hopfner (Pivotal bioVenture Partners), Derek DiRocco (RA Capital Management)
Ensoma
Series BJan 2023$85M
$260M
Co-investors: Kush Parmar (5am Ventures), Stephen Knight (F-Prime Capital Partners), Kouki Harasaki (M12 - Microsoft's Venture Fund)
Disc Medicine
Post Ipo EquityDec 2022$54M
Post Ipo EquitySep 2021$90M
$440M
Co-investors: Kevin Bitterman (Atlas Venture), Mona Ashiya (OrbiMed Advisors)
VelosBio
Series BJul 2020$140M
Series AOct 2018$58M
$200M
Co-investors: Joseph Anderson (Sofinnova Partners)
Imara
Series BMar 2019$63M
$63M
Co-investors: David Bonita (OrbiMed), Joseph Anderson (Sofinnova Partners)
Analyst JMI EquityPresent
Senior Business Analyst HotmailPresent
Manager HotmailPresent
Market Planning GenentechPresent
Corporate Development Gilead SciencesPresent
Consultant Boston Consulting Group (BCG)Present
Principal Longitude CapitalPresent
Investment Director HotmailPresent
Managing Director Arix Bioscience plcPresent
Partner Avoro CapitalPresent
University of California, San Diego BS Management Science and Computer Science
UC San Diego BS Management Science and Computer Science
University of Pennsylvania MSc Biotechnology
The Wharton School MBA Health Care Management